Abstract
Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) modifying agents have been involved in the development of intestinal inflammation, especially therapeutic monoclonal antibodies directed against CTLA-4. Here we report the appearance of a severe stricturing Crohn's disease-like colitis in a patient with a kidney allograft who was treated with belatacept, a recombinant CTLA-4-Ig fusion protein.
Keywords:
Belatacept; Colitis; Crohn’s disease; HHV-6; Inflammatory bowel disease.
MeSH terms
-
Abatacept / adverse effects*
-
CTLA-4 Antigen / antagonists & inhibitors
-
CTLA-4 Antigen / immunology
-
Colitis / chemically induced*
-
Colitis / diagnostic imaging
-
Colitis / drug therapy
-
Colitis / immunology
-
Colon / diagnostic imaging
-
Colon / immunology
-
Colonoscopy
-
Constriction, Pathologic / chemically induced
-
Constriction, Pathologic / immunology
-
Glucocorticoids / therapeutic use
-
Graft Rejection / immunology
-
Graft Rejection / prevention & control*
-
Humans
-
Immunosuppressive Agents / adverse effects*
-
Intestinal Mucosa / diagnostic imaging
-
Intestinal Mucosa / immunology
-
Intestinal Mucosa / pathology*
-
Kidney Failure, Chronic / surgery
-
Kidney Transplantation / adverse effects
-
Male
-
Middle Aged
-
Withholding Treatment
Substances
-
CTLA-4 Antigen
-
CTLA4 protein, human
-
Glucocorticoids
-
Immunosuppressive Agents
-
Abatacept